Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Schembri

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
The Journal of Family Planning and Reproductive Health Care|March 4, 2011
Risk factors for chlamydial infection in chlamydia contacts: a questionnaire-based studyGabriel Schembri, Paul Schober
Lancet (London, England)|January 4, 2011
Killing two birds with one stoneGabriel Schembri, Paul Schober
The Journal of Family Planning and Reproductive Health Care|January 16, 2015
Narratives of HIV: measuring understanding of HIV and the law in HIV-positive patientsMatthew D Phillips, Gabriel Schembri
International Journal of STD & AIDS|July 12, 2014
Should we screen heterosexuals for extra-genital chlamydial and gonococcal infections?Anna L Garner, Gabriel Schembri, Thomas Cullen, et al.
The Journal of Family Planning and Reproductive Health Care|April 10, 2009
Cervical surveillance in HIV-positive women: a genitourinary medicine clinic experienceFatima W Ibrahim, Gabriel Schembri, Huda Taha, et al.
Sexually Transmitted Infections|May 25, 2020
Test of cure study: a feasibility study to estimate the time to test of cure (TOC) for <i>Neisseria gonorrhoeae</i> and <i>Chlamydia trachomatis</i> infectionsBinta Sultan, Paul Benn, Gabriel Schembri, et al.
The Journal of Antimicrobial Chemotherapy|April 4, 2017
Randomized controlled trial of the tolerability and completion of maraviroc compared with Kaletra® in combination with Truvada® for HIV post-exposure prophylaxis (MiPEP Trial)Ana Milinkovic, Paul Benn, Alejandro Arenas-Pinto, et al.
HIV Clinical Trials|March 18, 2017
Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial<sup/>Frank A Post, Yazdan Yazdanpanah, Gabriel Schembri, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|April 23, 2020
Detection of the United States <i>Neisseria meningitidis</i> urethritis clade in the United Kingdom, August and December 2019 - emergence of multiple antibiotic resistance calls for vigilanceAvril Brooks, Jay Lucidarme, Helen Campbell, et al.
AIDS and Behavior|October 12, 2018
The Context of Sexual Risk Behaviour Among Men Who Have Sex with Men Seeking PrEP, and the Impact of PrEP on Sexual BehaviourMitzy Gafos, Rob Horne, Will Nutland, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
The Journal of Family Planning and Reproductive Health Care|March 4, 2011
Risk factors for chlamydial infection in chlamydia contacts: a questionnaire-based studyGabriel Schembri, Paul Schober
Lancet (London, England)|January 4, 2011
Killing two birds with one stoneGabriel Schembri, Paul Schober
The Journal of Family Planning and Reproductive Health Care|January 16, 2015
Narratives of HIV: measuring understanding of HIV and the law in HIV-positive patientsMatthew D Phillips, Gabriel Schembri
International Journal of STD & AIDS|July 12, 2014
Should we screen heterosexuals for extra-genital chlamydial and gonococcal infections?Anna L Garner, Gabriel Schembri, Thomas Cullen, et al.
The Journal of Family Planning and Reproductive Health Care|April 10, 2009
Cervical surveillance in HIV-positive women: a genitourinary medicine clinic experienceFatima W Ibrahim, Gabriel Schembri, Huda Taha, et al.
Sexually Transmitted Infections|May 25, 2020
Test of cure study: a feasibility study to estimate the time to test of cure (TOC) for <i>Neisseria gonorrhoeae</i> and <i>Chlamydia trachomatis</i> infectionsBinta Sultan, Paul Benn, Gabriel Schembri, et al.
The Journal of Antimicrobial Chemotherapy|April 4, 2017
Randomized controlled trial of the tolerability and completion of maraviroc compared with Kaletra® in combination with Truvada® for HIV post-exposure prophylaxis (MiPEP Trial)Ana Milinkovic, Paul Benn, Alejandro Arenas-Pinto, et al.
HIV Clinical Trials|March 18, 2017
Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial<sup/>Frank A Post, Yazdan Yazdanpanah, Gabriel Schembri, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|April 23, 2020
Detection of the United States <i>Neisseria meningitidis</i> urethritis clade in the United Kingdom, August and December 2019 - emergence of multiple antibiotic resistance calls for vigilanceAvril Brooks, Jay Lucidarme, Helen Campbell, et al.
AIDS and Behavior|October 12, 2018
The Context of Sexual Risk Behaviour Among Men Who Have Sex with Men Seeking PrEP, and the Impact of PrEP on Sexual BehaviourMitzy Gafos, Rob Horne, Will Nutland, et al.
Pageof 2